hotons from the sun reach our planet at high flux. In response, organisms have evolved detection systems that decode light information for adaptive advantage. Examples from mammals include the visual system 1 , where photons bouncing off an object are detected to decode object identity, and the circadian system, where the 24-h light cycle entrains time-of-day-dependent physiology 2, 3 . Most light detectors in metazoans are opsins 4, 5 , a class of G proteincoupled receptors that convert the energy of a photon into a cellular signalling response. Rhodopsin, the opsin of mammalian rod photoreceptors, is a well-characterized example of a visual opsin 6, 7 , whereas melanopsin (also known as opsin 4 (OPN4)) has a central role in circadian clock photoentrainment [8] [9] [10] . Neuropsin (also known as OPN5) is another opsin family member. Relatively little is known about OPN5 except that it responds to violet-light wavelengths (λ max of 380 nm) [11] [12] [13] [14] [15] , regulates seasonal breeding behaviour in birds 16 and the activity cycle in mice
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hotons from the sun reach our planet at high flux. In response, organisms have evolved detection systems that decode light information for adaptive advantage. Examples from mammals include the visual system 1 , where photons bouncing off an object are detected to decode object identity, and the circadian system, where the 24-h light cycle entrains time-of-day-dependent physiology 2, 3 . Most light detectors in metazoans are opsins 4, 5 , a class of G proteincoupled receptors that convert the energy of a photon into a cellular signalling response. Rhodopsin, the opsin of mammalian rod photoreceptors, is a well-characterized example of a visual opsin 6, 7 , whereas melanopsin (also known as opsin 4 (OPN4)) has a central role in circadian clock photoentrainment [8] [9] [10] . Neuropsin (also known as OPN5) is another opsin family member. Relatively little is known about OPN5 except that it responds to violet-light wavelengths (λ max of 380 nm) [11] [12] [13] [14] [15] , regulates seasonal breeding behaviour in birds 16 and the activity cycle in mice 17 , but also mediates photoentrainment of the retinal circadian clock 18 . Here, we have investigated OPN5 function in the development of the mouse eye and shown, like the above examples, that it is required for normal biological timing. In this case, OPN5 is required for a light response that regulates vascular regression timing.
Results
Opn5 is expressed in a retinal ganglion cell subset. Opn5 is expressed in retinal ganglion cells (RGCs) in adult mice 18 . To further assess the features of Opn5-expressing cells, we combined an Opn5 cre allele (Supplementary Fig. 1 ) with Ai14, a tdTomatoexpressing cre reporter. According to labelling with multiple markers ( Supplementary Fig. 2 ), the overall architecture of the Opn5-null retina is unchanged. In P5 (5 d postnatal) retinal flat mounts, Opn5 cre ; Ai14 cells were at relatively low density throughout the inner retina (Fig. 1a) . In P12 calretinin-labelled cryosections, Opn5-expressing cell bodies were in the ganglion cell layer (Fig. 1c,d ). At P5, Ai14-expressing processes were immature (Fig. 1a) , but at P12, the processes were prominent and observed as bundles within the nerve fibre layer (NFL) and within several laminations of the inner plexiform layer (IPL; S1-S5 (the sublaminae of the IPL); Fig. 1c,d ). These morphological features are consistent with the characteristics of RGCs.
OPN4 antibody labelling in Opn5 cre ; Ai14 retinae indicated that Opn4 and Opn5 are expressed in distinct RGC subsets. At P5, the density of Opn5 cre ; Ai14 and OPN4-labelled cells was similar (Fig. 1b) . At P12 (Fig. 1e-h ), co-labelling again showed that largely, Opn4 and Opn5 cre ; Ai14 cells were two distinct subsets. Prominent bundles of axons from Opn5 and Opn4 RGCs are cofasciculated ( Fig. 1e-g ). Rare co-labelled cells were identified ( ; Ai6 retinae at P8 with the RGC marker RBPMS (RNA-binding protein with multiple splicing) 21 and the RGC/amacrine cell marker calretinin 22 provided evidence that Opn5 is expressed exclusively in RGCs ( Supplementary Fig. 3 ).
Normal hyaloid vessel regression timing requires Opn5 and violet light. We have previously shown that light stimulation of Opn4 regulates hyaloid vessel regression and retinal angiogenesis 23 .
Prompted by this, we assessed hyaloid regression in the Opn5-null mouse. At P1, Opn5-null mice showed normal hyaloid vessel numbers (Fig. 2a,b ,g,h) and normal vessel cellularity (Fig. 2c,d , control: 13.3 ± 1.2, Opn5 null: 13.2 ± 1.6 nuclei per 100-μm length, P = 0.92). At P8, Opn5-null mice had fewer hyaloid vessels ( Fig. 2e-h ), indicating precocious regression. This phenotype is unique as all hyaloid phenotypes described so far 24 , including that of the Opn4-null mouse 23 , show hyaloid persistence. Precocious hyaloid regression in the Opn5-null mouse is best illustrated when vessel numbers are quantified over a P1-P8 time course (Fig. 2g ,h, blue line) and compared with the control (Fig. 2g ,h, grey line) and the Opn4-null mouse (Fig. 2h, green line) . When Opn5 fl is conditionally deleted in the retina using Chx10-cre or Rx-cre, precocious hyaloid regression is observed (Fig. 2i-k) . Thus, OPN5 is required locally within retinal neurons to regulate hyaloid regression.
To mimic Opn5 loss of function using lighting conditions, we raised mice from birth in the absence of the 380-nm wavelengths that maximally stimulate OPN5 (refs. [11] [12] [13] [14] ). Control mice were raised in a light-dark cycle of 'VBGR' (violet (380 nm), blue (480 nm), green (520 nm) and red (630 nm)) lighting and showed a typical hyaloid vessel number at P8 (Fig. 2l ,n, grey bar). By contrast, mice raised in 'BGR' lighting that omitted violet light showed precocious hyaloid regression (Fig. 2m ,n, blue bar). This phenocopies P = 0.002 15 12 Number of hyaloid vessels 16 ; Rx-cre mice. l,m, Hoechst 33258-labelled hyaloid vessel preparations from P8 mice raised from birth in full spectrum (VBGR) (l) or 'minus violet' (BGR) (m) lighting. n, Quantification of P8 hyaloid vessel number from P8 mice raised from birth in full spectrum (VBGR) or 'minus violet' (BGR) lighting. All P values were determined by Student's t-test; NS, not significant. The number at the base of each chart is n and represents the number of animals assessed. Error bars are s.e.m. Scale bars, 400 μm (a,b,e,f,i,j,l,m) and 20 μm (c,d).
the Opn5-null mice and is consistent with a model in which 380-nm photons stimulate OPN5 to suppress hyaloid vessel regression.
A light-OPN5 pathway regulates dopamine levels in the eye. In Opn4-null mice, elevated levels of vascular endothelial growth factor A (VEGFA) explain hyaloid vessel persistence 23 . Assessment of the levels of VEGFA and its inhibitor FLT1 (ref. 25 ) in the vitreous of Opn5-null mice indicated no change ( Supplementary Fig. 4d,e) . This suggested that the OPN5-light response pathway regulated hyaloid regression by a distinct mechanism. In the Opn5-null retina, we noted an unusual labelling pattern for tyrosine hydroxylase (TH). In wild-type (WT) retina at P8, TH immunoreactivity was faint and largely restricted to the perinuclear region of a subset of amacrine cells (Fig. 3a,b) . In Opn5-null mice, TH labelling was stronger and prominent in cell processes (Fig. 3c,d ). Elevated intensity of TH labelling in the Opn5-null retina was also evident at P15 when dopaminergic amacrine cells are more fully developed (Fig. 3e,f) . TH is the rate-limiting enzyme that mediates the first step in the biosynthesis of dopamine. As TH levels are under feedback regulation 26 , these data indicated that dopamine levels might be modulated in the Opn5-null eye. Interestingly, dopamine is known to have in vitro anti-vascular activity via suppression of VEGF receptor 2 (VEGFR2) signalling 27, 28 . This meant that Opn5-dependent regulation of dopamine could be an explanation for Opn5-dependent regulation of hyaloid regression. Thus, we hypothesized that OPN5-dependent release of dopamine from the retina promoted hyaloid vessel regression by direct signalling.
Dopaminergic amacrine cells that express TH develop in the first few days after birth in the mouse 29 . This also means that, normally, dopamine levels in the retina climb rapidly after birth 29 . Using enzyme-linked immunosorbent assay (ELISA) quantification, we confirmed that retinal dopamine levels rise over a P2-P8 time course (Fig. 3g) . Dopamine in solubilized retinal tissue is primarily from intracellular stores 30 . ELISA quantification showed that dopamine levels in the vitreous, where the hyaloid vessels reside, also rise over the postnatal period (Fig. 3h) . In adult mice, dopamine levels in the eye are light regulated [31] [32] [33] [34] . To evaluate this possibility for neonatal mice, we quantified vitreous dopamine over a postnatal time course of normal lighting and constant darkness. At P4 and P6, vitreal dopamine levels were significantly elevated in constant darkness ( Fig. 3i ), indicating that, postnatally, light stimulation normally suppresses vitreal dopamine. To determine whether lightregulated dopamine might be a consequence of OPN5 activity, we harvested retina and vitreous from an Opn5 allelic series at P6 and quantified dopamine levels ( Fig. 3j,k) . This showed that Opn5 homozygote null mice had lower levels of intracellular dopamine in the retina (Fig. 3j ), but elevated levels in the vitreous (Fig. 3k ). These data indicate that dopamine in both compartments is regulated by OPN5.
A light-OPN5 pathway suppresses dopamine release to the vitreous by enhancing DAT activity. The biological effects of dopamine are regulated by its release, signalling and reuptake 35, 36 . A key regulator of uptake, and thus a good candidate for an OPN5-dependent activity, is the dopamine transporter DAT (also known as SLC6A3) 36, 37 . Threonine 53 of DAT is phosphorylated and enhances the rate of dopamine uptake by DAT 37 . This activation marker can be detected with a phospho-specific antibody 37 . Basal phosphorylation stoichiometry of T53-DAT is typically 50% but is increased by stimuli that elevate dopamine uptake 37 . To determine whether phospho-T53-DAT levels were regulated by light and were OPN5 dependent, we labelled retinal cryosections from cohorts of P8 littermate Opn5 +/+ and Opn5 −/− mice after they were dark adapted followed by ±30 min of 380-nm light at 1 × 10 12 photons cm
. Labelling for phospho-T53-DAT was found throughout the IPL and NFL of all samples ( Fig. 4a-d) . The phospho-T53-DAT signal was quantified by averaging pixel intensity across horizontal pixel rows of images aligned like those shown ( Fig. 4a-d ), generating intensity profiles (Fig. 4e , grey and blue profiles) and calculating the area under the peaks (indicated by the grey vertical dashed lines in Fig. 4e,f) . This revealed that, for the IPL (Fig. 4g , grey and blue bars), but not for +/+ and Opn5 −/− mice during the light phase. Phospho-T53-DAT expression is lower than normal in the Opn5-null mice. The unprocessed blot image is available in Supplementary Fig. 6 . j, Quantification of P8 hyaloid vessels in WT mice injected with vehicle (veh) or with the DAT inhibitor (DATi) raised from E17 either in normal lighting or in constant darkness. k, Quantification of P8 hyaloid vessels in Opn5
+/− and Opn5 −/− mice injected from P1-P8 with the DAT inhibitor. P values were determined by two-way ANOVA. Error bars are s.e.m. The number at the base of each chart is n and represents the number of animals assessed. Panels a-d are representative of three separate experiments.
the NFL (Fig. 4h, grey and blue bars) , the phospho-T53-DAT signal was significantly increased in response to the 380-nm light.
To determine whether light induction of the phospho-T53-DAT signal was OPN5 dependent, we performed the same analysis in Opn5-null mice (Fig. 4c,d,f-h ). This revealed that, in the Opn5-null retina, the phospho-T53-DAT signal for the IPL did not elevate in response to light exposure (Fig. 4g , orange and red bars), indicating OPN5 dependence. Interestingly, in the NFL, Opn5-null mice have a lower level of phospho-T53-DAT independent of light exposure (Fig. 4h , compare grey bar and orange bar). However, this low level of phospho-T53-DAT can be rescued by light exposure (Fig. 4h , compare orange and red bars). This indicates that NFL phospho-T53-DAT levels are regulated both by OPN5 (negatively, light independent) and by a distinct light response pathway (positively). Although we do not currently understand the pathway for the positive regulation of phospho-T53-DAT in the NFL (other opsins are obvious candidates), it serves as a useful internal control to show that the Opn5-null retina can be light responsive. An immunoblot detecting phospho-T53-DAT in total solubilized retina from the light phase (Fig. 4i) revealed that, overall, the level is lower in the Opn5-null mice, suggesting that NFL phospho-T53-DAT is the smaller proportion of the total. Collectively, analysis of T53-DAT indicates that OPN5 is required for a light-dependent upregulation within the IPL. As T53-phosphorylated DAT sequesters dopamine with higher efficiency, this finding is consistent with a model in which loss of OPN5 function results in diminished dopamine uptake by DAT, and thus elevated levels of vitreal dopamine.
Inhibition of DAT promotes hyaloid regression in an Opn5-dependent manner. To determine whether DAT had a functional role in the regulation of hyaloid regression in vivo, we took advantage of the DAT inhibitor GBR12909 (ref. 38 ). Based on data showing that dopamine signalling can suppress VEGFR2 activation via the phosphatase SHP2 (ref. 28 ), we would predict that suppressing DAT activity would elevate dopamine levels in the eye and thus should counter the consequences of dark rearing because the latter elevates levels of VEGFA 39 . To test this, we compared the effects of P1-P8 GBR12909 injection on hyaloid vessel regression in C57BL/6J mice raised either in normal lighting or in constant darkness. This showed that GBR12909 had no significant effect on mice raised in normal lighting (Fig. 4j, normal lighting) , but could reverse the hyaloid vessel persistence resulting from dark rearing (Fig. 4j, constant darkness) . This shows that DAT activity is an important lightdependent regulator of hyaloid vessel regression.
To assess DAT activity in OPN5-dependent regulation of hyaloid regression, we injected GBR12909 daily from P1-P8 into Opn5
Opn5
+/− and Opn5 −/− mouse pups. Quantification of hyaloid vessels at P8 showed that WT mice did not respond significantly (Fig. 4k) , but that in heterozygote mice, GBR12909 produced a precocious hyaloid regression equivalent to the Opn5 homozygote phenotype (Fig. 4k) . GBR12909 produced no change in homozygote mice (Fig. 4k) . Inhibitor activity may be buffered by the intact feedback regulation of the WT mouse 40 . However, in Opn5 heterozygote mice, in which dopamine levels are elevated (Fig. 3k) and feedback regulation may be compromised, the DAT inhibitor was able to convert the hyaloid phenotype from normal to precocious regression. It is likely that the inhibitor produces no effect in the Opn5 homozygote because the endogenous vitreal dopamine level is already high (Fig. 3k) and signalling activity may be close to maximal. These data indicate a finely balanced interaction between OPN5 and DAT that is consistent with OPN5-dependent regulation of DAT activity via phosphorylation.
VGAT in OPN5 RGCs is required for regulation of phospho-T53-DAT and hyaloid regression. Glutamate, γ-aminobutyric acid (GABA) and glycine are neurotransmitters important for visual function. In the adult mouse, glutamate is used as an excitatory neurotransmitter by canonical photoreceptors 41, 42 and OPN4 RGCs 43 . GABA and glycine are inhibitory neurotransmitters and their receptors are detected in various retinal neurons, including amacrine cells and RGCs 42 . Glutamate and GABA/glycine are loaded into presynaptic vesicles by the VGLUT (vesicular glutamate transporter) and VGAT (vesicular GABA transporter) family of transporters, respectively. During mouse retinal development, VGAT is expressed soon after birth and precedes the expression of VGLUT2 (ref. 44 ). Loss of function of these transporters eliminates neurotransmitter activity 45, 46 . To determine whether OPN5 RGCs might use one of these neurotransmitters for the vascular response pathway, we quantified hyaloid vessels in Opn5 cre conditional deletion mutants of Vglut2 and Vgat. Although deletion of Vglut2 fl had no consequence (Fig. 5a ), homozygous deletion of Vgat fl phenocopied the Opn5 germline null precocious hyaloid regression (Fig. 5b-f) . Furthermore, the Opn5 cre/+ heterozygote showed no hyaloid phenotype, but Opn5
+/cre
; Vgat fl/+ mice showed a significant precocious regression (Fig. 5d,f) . This transheterozygote phenotype is genetic evidence that Opn5 and Vgat function in the same pathway and in the same cell type. If this is true, then we would predict that the Vgat conditional deletion would, like Opn5 loss of function, result in diminished levels of phospho-T53-DAT under lighted conditions. This was confirmed using immunofluorescence labelling of the retina from Opn5 +/cre ; Vgat fl/+ (Fig. 5g,h ) and Opn5
; Vgat fl/fl mice (Fig. 5i,j) . These data indicate that OPN5 RGCs use VGAT to signal within the vascular regression pathway.
Dopamine has a direct action on hyaloid vascular endothelial cells to promote hyaloid regression.
We have hypothesized that dopamine release from the neonatal retina is light and OPN5 dependent and that dopamine then signals directly to hyaloid vascular endothelial cells (VECs) to promote regression. To assess whether a retinal source of dopamine regulated hyaloid regression, we conditionally deleted a Th fl allele. Chx10-cre 47 , although effective for studies of TH function in adult mice 48 , did not delete Th fl efficiently during the postnatal period. However, Rx-cre 49 was effective (Fig. 6a,b ) and resulted in a hyaloid vessel persistence (Fig. 6c-e) , indicating that the active dopamine is produced locally in the retina.
To assess the involvement of dopamine receptors in hyaloid regression, we first took advantage of SK38393, a receptor agonist 50 .
SK38393 was injected daily into Opn5
+/− and Opn5
−/−
mouse pups from P1-P8. Although SK38393 had no significant effect on WT mice ( Supplementary Fig. 4f ), it produced precocious hyaloid regression in heterozygous mice ( Supplementary Fig. 4f ). SK38393 did not produce a significant reduction in hyaloid vessel numbers in Opn5-null mice (Supplementary Fig. 4f ). This pattern of response is very similar to that observed with the DAT inhibitor (Fig. 4k) . Again, this pattern of modulation is probably explained by the resilience of an intact dopamine feedback pathway in WT animals, the sensitized background of the heterozygote and the already saturated level of dopamine signalling in the homozygote. Injection of two different dopamine receptor antagonists from P1-P8 in WT mice produced elevated numbers of hyaloid vessels ( Supplementary  Fig. 4g ). Thus, pharmacological manipulations indicate that hyaloid vessel regression can be regulated both positively and negatively by dopamine receptor modulators. One prediction of the hypothesis that retinal dopamine regulates hyaloid regression was that dopamine receptors would be expressed within the hyaloid vessels. As dopamine receptor D 2 (DRD2) was implicated in the suppression of VEGFR2 signalling 28 , we focused on this member of the family. Vascular cells, but not hyaloid-associated myeloid cells, showed Drd2-GFP reporter expression (Fig. 6f,g ). Furthermore, labelling with an anti-DRD2 antibody detected cells within the hyaloid vessels (Fig. 6h) and this was eliminated in the Drd2 fl/fl ; Pdgfb-icreERT2 conditional deletion that targets VECs (Fig. 6i) . These data show that DRD2 is expressed in hyaloid VECs.
In Drd2
fl/fl
; Pdgfb-icreERT2 mice, the hyaloid vessels are persistent (Fig. 6j) , but there are no quantifiable consequences for the development of the superficial retinal vasculature ( Supplementary  Fig. 5 ). This identifies hyaloid VECs as a dopamine-responsive cell and indicates that dopamine signalling promotes hyaloid regression. A further prediction of the hypothesis is that, in hyaloid VECs, dopamine signalling would suppress the activation of VEGFR2 (ref. ; Pdgfb-icreERT2 hyaloid vessels at P5. Pooling dissected hyaloids from six animals of each genotype allowed threshold detection of the pY1173-VEGFR2 in the control (Fig. 6k, left lane) . To assess the reliability of comparative immunoblotting, we performed a three step, twofold loading dilution and quantified immunoblot band intensities. Presented graphically, band intensities for VEGFR2, pY1173-VEGFR2 and β-tubulin showed high Pearson coefficients, indicating a linear relationship between lysate quantity and band intensity ( Supplementary  Fig. 6 ). When pY1173-VEGFR2 values were normalized to VEGFR2 (Fig. 6l) , Drd2 fl/fl ; Pdgfb-icreERT2 genotype values were much higher (Fig. 6l) , consistent with the observed band intensities on the immunoblot (Fig. 6k) . These data show that deletion of Drd2 in hyaloid VECs permits elevated activation of VEGFR2 and indicates that, normally, dopamine signalling suppresses VEGFR2 activity. In an additional test of this model, we assessed pY1173-VEGFR2 and pS473-AKT levels in the Opn5-null mice. pY1173-VEGFR2 levels were lower in the hyaloid vessels of the Opn5-null mice (Fig. 6m) . In addition, across an allelic series, pS473-AKT levels were lower only in the Opn5 homozygote, consistent with precocious hyaloid regression only in this genotype (Fig. 6n) . As dopamine levels are high in the Opn5-null mice, these data are consistent with a model in which dopamine promotes hyaloid vessel regression by suppressing VEGFR2 activity and the downstream survival signalling mediated by AKT.
As a genetic test of the relationship between OPN5 and vascular signalling, we determined whether deletion of Drd2 in VECs would reverse precocious hyaloid regression in the Opn5-null mice. We compared P8 hyaloid vessel numbers in mice of genotype Opn5 . This experiment confirmed the precocious regression of hyaloid vessels due to Opn5 loss of function (Fig. 6o,p,r, light blue bar) , but showed that deletion of Drd2 in VECs could switch the hyaloid phenotype to persistence (Fig. 6q,p , dark blue bar). This outcome establishes that Opn5 and Drd2 function in the same developmental pathway and have opposing influences on hyaloid regression.
One implication of immunoblotting data for pY1173-VEGFR2 (Fig. 6k) and the genetic analysis (Fig. 6o-r) is that a balance of VEGFA and dopamine signalling determines the fate of the hyaloid vessels. To determine whether we could demonstrate this balance at the level of receptor ligands, we designed a rescue experiment. We generated an elevated level of VEGFA activity, and thus hyaloid vessel persistence, by conditionally deleting the gene encoding the naturally occurring VEGFA inhibitor FLT1 in the retina. Chx10-cre deletion of Flt1 fl/fl produces hyaloid persistence ( Supplementary  Fig. 4a-c) , but in this case, we used Rx-cre (Fig. 6s,t,v, light blue bar) . To determine whether dopamine receptor signalling could reverse the hyaloid persistence, we injected (each day, from P1 to P8) a littermate cohort of Rx-cre; Flt1 fl/fl mice with the dopamine receptor agonist SKF38393. This resulted in a reversal of the hyaloid persistence (Fig. 6s-v) , an outcome that illustrates the balance of VEGFA and dopamine signalling that regulates hyaloid regression. ; Pdgfb-icreERT2 mice. Hyaloid lysate is loaded in successively halved volumes to ensure linear range detection. l, Band intensity of n = 3 mice, pY1173-VEGFR2, normalized to total VEGFR2 from k confirms that, in the Drd2 mutant, active VEGFR2 expression is higher. m,n, Immunoblots for VEGFR2 and pY1173-VEGFR2 (m), and AKT and pS473-AKT (n) from P6 hyaloids of the indicated genotypes. In the graph in m, quantification of pY1173-VEGFR2 relative to VEGFR2 in Opn5 +/+ and Opn5 −/− hyaloid vessels is shown. pY1173-VEGFR2 and pS473-AKT levels are lower in Opn5
. n = 3 mice. Unprocessed blot images are shown in Supplementary Fig. 6 . o-q, P8 hyaloids from tamoxifen-treated Opn5 
Discussion
We have identified an unanticipated vascular development pathway in the eye. OPN5, an atypical opsin known to respond to near-UV photons [11] [12] [13] [14] , initiates the pathway response and functions postnatally (Fig. 5l) . Dopamine, a broadly functional neurotransmitter and neuromodulator, is a signalling intermediate that is regulated by OPN5 and elicits a direct response in hyaloid VECs to limit VEGFR2 signalling via DRD2 (Fig. 5l) . Based on OPN5-dependent and light-dependent phosphorylation at T53, and its pharmacological inhibition, our data also indicate that the dopamine transporter DAT is a key component of this pathway that normally suppresses the levels of dopamine in the vitreous (Fig. 5l) . In addition, the GABA transporter VGAT is implicated in OPN5 RGC signalling as its conditional deletion in OPN5 RGCs phenocopies the Opn5-null precocious hyaloid regression and low phospho-T53-DAT level. Thus, the light-OPN5-VGAT-dopamine-DRD2-VEGFR2-hyaloid pathway is characterized by two suppressive steps: light-OPN5 suppresses the levels of dopamine in the vitreous, whereas dopamine suppresses VEGFR2 signalling in the hyaloid vessels (Fig. 5l) .
Light-dependent regulation of vitreal dopamine occurs against a backdrop of generally rising levels of dopamine in the postnatal eye. This means that, whereas the function of dopamine is to promote hyaloid vessel regression, the effect of 380-nm photons and OPN5 is to suppress regression of the hyaloid vessels. It is likely that this has evolved as a mechanism to optimize the timing of hyaloid vessel regression and ensure that they remain functional postnatally until the superficial retinal vascular plexus is complete. We have previously shown that OPN4 also mediates light-dependent vascular development in the eye 39 and suppresses VEGFA levels because it keeps retinal cellularity in check, and thus limits the oxygen demand that can elevate levels of VEGFA (Fig. 5l) . The crucial window for activation of the OPN4 response is in late gestation and requires a direct light stimulation of the mouse fetus 39 . Thus, the OPN4 and OPN5 response pathways use distinct mediators to regulate vascular development and, as they function at different stages of development, can be thought of as developmental timing cues (Fig. 5l) . Notably, the spontaneous waves of neuronal activity that arise in the neonatal mouse retina 52, 53 are partly dependent on OPN4 modulation of gap junctions that are, in turn, regulated by dopamine 54 . In the future, it will be interesting to assess the relationship of retinal wave activity to vascular development.
OPN5 is highly conserved and we might anticipate that the pathway that we describe (Fig. 5l) will be relevant to human biology. The latter steps in the pathway involving DRD2-dependent suppression of VEGFR2 activity may be an explanation for the observation that premature infants treated with dopamine (for hypotension) have a higher risk of retinopathy of prematurity 55, 56 , a vascular overgrowth disease. We suggest that therapeutic dopamine promotes regression of the hyaloid vessels and thus exacerbates the hypoxia that leads to rebound vascular overgrowth. Furthermore, we have previously shown that the risk of retinopathy of prematurity in premature infants is partly dependent on their season of gestation, with short days and lower light exposure associated with higher risk 57 . It is possible that the OPN5-dopamine pathway is a component of this risk equation because insufficient light would be expected to result in elevated levels of vitreal dopamine, precocious hyaloid regression and thus a more profound hypoxia in the premature eye. An understanding of the relationship between OPN4-dependent and OPN5-dependent regulation of vascular development in the eye (Fig. 5l) raises the interesting possibility that premature infants at risk for retinopathy of prematurity might be treated with a light therapy that differentially targets each pathway response. Finally, it has been proposed that both violet light in the 360-400-nm range 58 and dopamine 59 are key regulators of refractive development and that each can suppress progression to myopia. The current observations suggest that the OPN5-dopamine pathway is likely to be involved. Last updated by author(s): Feb 7, 2019 Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.
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